News | September 10, 2025
Sirio secures TGA GMP certification to support strategic growth in Australia
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Subscribe To Our Newsletter & Stay Updated
